CSR Synopses following approval of a new medicine or a new indication for an approved medicine in the US or EU. We are making CSR synopses available to supplement the public information available to patients and healthcare providers about the results of our clinical trials and the evidence used to approve a new medicine or a new indication.
Venclexta
Study Name | |||
---|---|---|---|
M14-212
|
Acute Myelogenous Leukemia (AML) | Phase 2 | A Phase 2 Study of ABT-199 in Subjects with Acute Myelogenous Leukemia (AML) |
M13-364
|
Non-Hodgkin lymphoma | Phase 1 | A Phase 1 Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of ABT-199 |